| Outcome Measures: |
Primary: Change From Baseline in Glycated Haemoglobin (HbA1c) (Week 52), Change from baseline (week 0) in glycosylated haemoglobin (HbA1c) was evaluated at week 52. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of additional anti-diabetic medication or discontinuation of trial treatment. Percentage point refers to arithmetic difference between two percentages., Baseline (week 0), week 52 | Secondary: Change From Baseline in Body Weight (Week 52), Change from baseline (week 0) in body weight was evaluated at week 52. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of additional anti-diabetic medication or discontinuation of trial treatment., Baseline (week 0), week 52|Change From Baseline in HbA1c (Week 68), Change from baseline (week 0) in HbA1c was evaluated at week 68. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of additional anti-diabetic medication or discontinuation of trial treatment. Percentage point refers to arithmetic difference between two percentages., Baseline (week 0), week 68|Change From Week 12 in HbA1c (Week 52), Change in HbA1c was evaluated from week 12 to week 52. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of additional anti-diabetic medication or discontinuation of trial treatment. Percentage point refers to arithmetic difference between two percentages., Week 12, Week 52|Change From Baseline in Fasting Plasma Glucose (FPG) (Week 52), Change from baseline (week 0) in fasting plasma glucose (FPG) was evaluated at week 52. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of additional anti-diabetic medication or discontinuation of trial treatment., Baseline (week 0), week 52|Change From Baseline in FPG (Week 68), Change from baseline (week 0) in FPG was evaluated at week 68. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of additional anti-diabetic medication or discontinuation of trial treatment., Baseline (week 0), week 68|Percentage of Participants Who Achieved HbA1c Less Than (<) 7.0 (Percent [%]) (Week 52), Percentage of participants who achieved HbA1c \<7.0 % at week 52 are presented. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of additional anti-diabetic medication or discontinuation of trial treatment., At week 52|Percentage of Participants Who Achieved HbA1c < 7.0 % (Week 68), Percentage of participants who achieved HbA1c \<7.0 % at week 68 are presented. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of additional anti-diabetic medication or discontinuation of trial treatment., At week 68|Percentage of Participants Who Achieved HbA1c Less Than or Equal to (<=) 6.5 % (Week 52), Percentage of participants who achieved HbA1c \<=6.5 % at week 52 are presented. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of additional anti-diabetic medication or discontinuation of trial treatment., At week 52|Percentage of Participants Who Achieved HbA1c <= 6.5 % (Week 68), Percentage of participants who achieved HbA1c \<=6.5 % at week 68 are presented. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of additional anti-diabetic medication or discontinuation of trial treatment., At week 68|Time to Event Analyses of Rescue Medication, Time to event analyses of rescue medication was evaluated from baseline (week 0) to week 68. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of additional anti-diabetic medication or discontinuation of trial treatment., Baseline (week 0), week 68|Change From Baseline in Body Weight (Week 68), Change from baseline (week 0) in body weight was evaluated at week 68. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of additional anti-diabetic medication or discontinuation of trial treatment., Baseline (week 0), week 68|Percentage Change From Baseline in Body Weight (Week 52), Percentage change from baseline (week 0) in body weight was evaluated at week 52. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of additional anti-diabetic medication or discontinuation of trial treatment., Baseline (week 0), week 52|Percentage Change From Baseline in Body Weight (Week 68), Percentage change from baseline (week 0) in body weight was evaluated at week 68. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of additional anti-diabetic medication or discontinuation of trial treatment., Baseline (week 0), week 68|Percentage Change From Week 12 in Body Weight (Week 52), Percentage change in body weight was evaluated from week 12 to week 52. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of additional anti-diabetic medication or discontinuation of trial treatment., Week 12, Week 52|Change From Baseline in Body Mass Index (BMI) (Week 52), Change from baseline (week 0) in body mass index (BMI) was evaluated at week 52. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of additional anti-diabetic medication or discontinuation of trial treatment., Baseline (week 0), week 52|Change From Baseline in BMI (Week 68), Change from baseline (week 0) in BMI was evaluated at week 68. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of additional anti-diabetic medication or discontinuation of trial treatment., Baseline (week 0), week 68|Change From Baseline in Waist Circumference (Week 52), Change from baseline (week 0) in waist circumference was evaluated at week 52. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of additional anti-diabetic medication or discontinuation of trial treatment., Baseline (week 0), week 52|Change From Baseline in Waist Circumference (Week 68), Change from baseline (week 0) in waist circumference was evaluated at week 68. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of additional anti-diabetic medication or discontinuation of trial treatment., Baseline (week 0), week 68|Percentage of Participants Who Achieved Weight Loss Greater Than or Equal to (>=) 5 % (Week 52), Percentage of participants who achieved weight loss \>= 5 % at week 52 are presented. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of additional anti-diabetic medication or discontinuation of trial treatment., At week 52|Percentage of Participants Who Achieved Weight Loss >= 5 % (Week 68), Percentage of participants who achieved weight loss \>= 5 % at week 68 are presented. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of additional anti-diabetic medication or discontinuation of trial treatment., At week 68|Percentage of Participants Who Achieved Weight Loss >= 10 % (Week 52), Percentage of participants who achieved weight loss \>= 10 % at week 52 are presented. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of additional anti-diabetic medication or discontinuation of trial treatment., At week 52|Percentage of Participants Who Achieved Weight Loss >= 10 % (Week 68), Percentage of participants who achieved weight loss \>= 10 % at week 68 are presented. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of additional anti-diabetic medication or discontinuation of trial treatment., At week 68|Change From Baseline in Total Cholesterol (Week 52), Change from baseline (week 0) in total cholesterol was evaluated at week 52. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of additional anti-diabetic medication or discontinuation of trial treatment., Baseline, Week 52|Change From Baseline in Total Cholesterol (Week 68), Change from baseline (week 0) in total cholesterol was evaluated at week 68. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of additional anti-diabetic medication or discontinuation of trial treatment., Baseline, Week 68|Change From Baseline in Low Density Lipoproteins (LDL) (Week 52), Change from baseline (week 0) in LDL was evaluated at week 52. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of additional anti-diabetic medication or discontinuation of trial treatment., Baseline, Week 52|Change From Baseline in LDL (Week 68), Change from baseline (week 0) in LDL was evaluated at week 68. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of additional anti-diabetic medication or discontinuation of trial treatment., Baseline, Week 68|Change From Baseline in High Density Lipoproteins (HDL) (Week 52), Change from baseline (week 0) in HDL was evaluated at week 52. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of additional anti-diabetic medication or discontinuation of trial treatment., Baseline, Week 52|Change From Baseline in HDL (Week 68), Change from baseline (week 0) in HDL was evaluated at week 68. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of additional anti-diabetic medication or discontinuation of trial treatment., Baseline, Week 68|Change From Baseline in Triglycerides (Week 52), Change from baseline (week 0) in triglycerides was evaluated at week 52. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of additional anti-diabetic medication or discontinuation of trial treatment., Baseline, Week 52|Change From Baseline in Triglycerides (Week 68), Change from baseline (week 0) in triglycerides was evaluated at week 68. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of additional anti-diabetic medication or discontinuation of trial treatment., Baseline, Week 68|Number of Adverse Events, An adverse event (AE) defined as any unfavourable and unintended sign, including an abnormal laboratory finding, symptom or disease (new or exacerbated) temporally associated with the use of an investigational medicinal products (IMP). Results are based on the data from the on-treatment observation period, which was the time period when a participant was on trial treatment, including any period after initiation of rescue medication., From baseline (week 0) up to week 73|Number of Clinically Significant Hypoglycaemic Episodes (Level 2) (<3.0 mmol/L (54 Milligram Per Decilitre [mg/dL]) or Severe Hypoglycaemic Episodes (Level 3), Hypoglycaemic episodes were classified according to the American Diabetes Association 2018/ International Hypoglycaemia Study Group 2017, where glycemic criteria for level 2 was \< 3.0 mmol/L (54 mg/dL) and level 3 had no specific glucose threshold. Results are based on the data from the on-treatment observation period, which was the time period when a participant was on trial treatment, including any period after initiation of rescue medication., From baseline (week 0) up to week 68|Change From Baseline in Systolic Blood Pressure (Week 52), Change from baseline (week 0) in systolic blood pressure at week 52 are presented. Results are based on the data from the on-treatment observation period, which was the time period when a participant was on trial treatment, including any period after initiation of rescue medication., Baseline (week 0), week 52|Change From Baseline in Systolic Blood Pressure (Week 68), Change from baseline (week 0) in systolic blood pressure at week 68 are presented. Results are based on the data from the on-treatment observation period, which was the time period when a participant was on trial treatment, including any period after initiation of rescue medication., Baseline (week 0), week 68|Change From Baseline in Diastolic Blood Pressure (Week 52), Change from baseline (week 0) in diastolic blood pressure at week 52 are presented. Results are based on the data from the on-treatment observation period, which was the time period when a participant was on trial treatment, including any period after initiation of rescue medication., Baseline (week 0), week 52|Change From Baseline in Diastolic Blood Pressure (Week 68), Change from baseline (week 0) in diastolic blood pressure at week 68 are presented. Results are based on the data from the on-treatment observation period, which was the time period when a participant was on trial treatment, including any period after initiation of rescue medication., Baseline (week 0), week 68|Change From Baseline in Pulse (Week 52), Change from baseline (week 0) in pulse at week 52 are presented. Results are based on the data from the on-treatment observation period, which was the time period when a participant was on trial treatment, including any period after initiation of rescue medication., Baseline (week 0), week 52|Change From Baseline in Pulse (Week 68), Change from baseline (week 0) in pulse at week 68 are presented. Results are based on the data from the on-treatment observation period, which was the time period when a participant was on trial treatment, including any period after initiation of rescue medication., Baseline (week 0), week 68
|
| Locations: |
American Clinical Trials, Buena Park, California, 90620, United States|Valley Research, Fresno, California, 93720, United States|Velocity Clin Res San Diego, La Mesa, California, 91942, United States|First Valley Medical Group, Lancaster, California, 93534, United States|Pacific Clinical Studies, Los Alamitos, California, 90720, United States|Velocity Clin Res Wstlke, Los Angeles, California, 90057, United States|Desert Oasis Hlthcr Med Group, Palm Springs, California, 92262, United States|Gateway Research Center, Poway, California, 92064, United States|Encompass Clinical Research_Spring Valley, Spring Valley, California, 91978, United States|Diablo Clinical Research, Inc., Walnut Creek, California, 94598, United States|San Fernando Valley Hlth Inst, West Hills, California, 91304, United States|Optumcare Colorado Springs, Colorado Springs, Colorado, 80906, United States|Chase Medical Research LLC, Waterbury, Connecticut, 06708, United States|Northeast Research Institute, Jacksonville, Florida, 32204, United States|San Marcus Res Clin Miami Lakes, Miami Lakes, Florida, 33014, United States|Complete Health Research, Ormond Beach, Florida, 32174-6302, United States|Endo Res Solutions Inc, Roswell, Georgia, 30076, United States|East West Med Res Inst, Honolulu, Hawaii, 96814, United States|Elite Clinical Trials, Blackfoot, Idaho, 83221, United States|Solaris Clinical Research, Meridian, Idaho, 83646, United States|Cedar-Crosse Research Center, Chicago, Illinois, 60607, United States|Macoupin Research Group, Gillespie, Illinois, 62033, United States|Evanston Premier Hlthcr Res, Skokie, Illinois, 60077, United States|Midwest Inst For Clin Res, Indianapolis, Indiana, 46260, United States|Iowa Diab & Endo Res Center, West Des Moines, Iowa, 50266, United States|Cotton O'Neil Clin Research Ctr, Topeka, Kansas, 66606, United States|The Research Group of Lexington LLC, Lexington, Kentucky, 40503, United States|L-MARC Research Center, Louisville, Kentucky, 40213, United States|MD Medical Research, Oxon Hill, Maryland, 20745, United States|Brigham & Women's Hospital, Boston, Massachusetts, 02115-5804, United States|MassResearch, LLC, Waltham, Massachusetts, 02453, United States|Aa Mrc Llc, Flint, Michigan, 48504, United States|Arcturus Healthcare, PLC., Troy, Michigan, 48098, United States|Mercury Str Med Grp, PLLC, Butte, Montana, 59701, United States|Premier Research Inc., Trenton, New Jersey, 08611, United States|Accellacare, Wilmington, North Carolina, 28401, United States|Lillestol Research LLC, Fargo, North Dakota, 58104, United States|Prestige Clinical Research, Franklin, Ohio, 45005, United States|Albert J Weisbrot, Mason, Ohio, 45040, United States|Intend Research, Norman, Oklahoma, 73069, United States|Corvallis Clinic PC Clinical Research Department, Corvallis, Oregon, 97330-3737, United States|Preferred Primary Care Physicians_Pittsburgh, Pittsburgh, Pennsylvania, 15236, United States|Holston Medical Group Pc, Bristol, Tennessee, 37620-7352, United States|Chattanooga Medical Research, LLC, Chattanooga, Tennessee, 37404, United States|Clinical Neuroscience Solutions, Memphis, Tennessee, 38119, United States|Arlington Family Res. Ctr Inc, Arlington, Texas, 76012-4637, United States|Velocity Clinical Res-Dallas, Dallas, Texas, 75230, United States|Velocity Clinical Research, Dallas, Dallas, Texas, 75230, United States|UT Southwestern Med Cntr, Dallas, Texas, 75390-9302, United States|Juno Research, LLC_Houston, Houston, Texas, 77074, United States|DCOL Ctr for Clin Res, Longview, Texas, 75605, United States|Research Institute Of Dallas, Plano, Texas, 75093, United States|VIP Trials, San Antonio, Texas, 78230, United States|Consano Clinical Research, LLC, Shavano Park, Texas, 78231, United States|York Clinical Research LLC, Norfolk, Virginia, 23504, United States|Dominion Medical Associates, Richmond, Virginia, 23219, United States|Capital Clin Res Ctr,LLC, Olympia, Washington, 98502, United States|Liverpool Hospital, Liverpool, New South Wales, 2170, Australia|Royal Brisbane and Women's Hospital, Herston, Queensland, 4029, Australia|Core Research Centre, Milton, Queensland, 4064, Australia|South Australian Endocrine Research, Keswick, South Australia, 5035, Australia|Southern Adelaide Diabetes & Endocrine Services, Oaklands Park, South Australia, 5046, Australia|Barwon Health (The Geelong Hospital), Geelong, Victoria, 3220, Australia|"MHAT-Blagoevgrad", Department of Internal Diseases, Blagoevgrad, 2700, Bulgaria|Medical Center Zdrave Lom, Lom, 3600, Bulgaria|UMHAT Pulmed, Department of endocrinology, Pazardzhik, 4400, Bulgaria|"MHAT - Pazardzhik", Pazardzhik, 4401, Bulgaria|OCSOMCE - Dr. Albena Dinkova EOOD, Pleven, 5800, Bulgaria|UMHAT "Kaspela", Depart. Endocrinology and Metab. Diseases, Plovdiv, 4001, Bulgaria|'MHAT Sveta Karidad' EAD, Plovdiv, 4004, Bulgaria|'MHAT Hadzhi Dimitar' OOD, Sliven, 8800, Bulgaria|"Medical center Smolyan clinical research" OOD, Smolyan, 4700, Bulgaria|UMHAT "Aleksandrovska", Sofia, 1431, Bulgaria|USHATE "Akad. Ivan Penchev" Second Clinic of Endocrinology, Sofia, 1431, Bulgaria|Medical Institute of Ministry of interior, Sofia, 1606, Bulgaria|UMHAT Sveta Marina EAD, Varna, 9010, Bulgaria|AIPSMC Dr. Artin Magardichyan EOOD, Varna, 9020, Bulgaria|MHAT- Hristo Botev, Vratsa, 3001, Bulgaria|"MHAT "Sveti Panteleimon" - Yambol" AD, Yambol, 8600, Bulgaria|LMC Clin Res Inc. Calgary, Calgary, Alberta, T2H 2G4, Canada|C-endo Diab Endo Clin Calgery, Calgary, Alberta, T2V 4J2, Canada|G.A. Research Associates Ltd., Moncton, New Brunswick, E1G 1A7, Canada|LMC ClinRsrh Inc.Brampton, Brampton, Ontario, L6S 0C6, Canada|LMC Clinical Res Thornhill, Concord, Ontario, L4K 4M2, Canada|LMC Endo Ctr (Etobicoke) Ltd, Etobicoke, Ontario, M9R 4E1, Canada|Wharton Med Clin Trials, Hamilton, Ontario, L8L 5G8, Canada|LMC Research Inc. Ottawa, Nepean, Ontario, K2J 0V2, Canada|LMC Oakville, Oakville, Ontario, L6M 1M1, Canada|Winterberry Family Medicine, Stoney Creek, Ontario, L8J 0B6, Canada|LMC Endo Centres Ltd.(Bayview), Toronto, Ontario, M4G 3E8, Canada|Applied Med Inf Res, Montreal, Quebec, H4A 3T2, Canada|LMC Clin Rsrch Inc. (Montreal), Saint-Laurent, Quebec, H4T 1Z9, Canada|Poliklinika Solmed, Zagreb, Grad Zagreb, 10000, Croatia|KBC Rijeka, Endokrinologija, Rijeka, Primorsko - Goranska Županija, 51 000, Croatia|Klinicki bolnicki centar Osijek, Osijek, 31 000, Croatia|Opca bolnica Dr. Josip Bencevic, Slavonski Brod, 35 000, Croatia|KB Dubrava, Zavod za endokrinologiju i dijabetes, Zagreb, 10000, Croatia|Klinicka bolnica Sveti Duh, Zagreb, 10000, Croatia|Ordinace pro choroby srdce, Chomutov, 430 02, Czechia|Diahaza s.r.o., Holešov, 76901, Czechia|DIALINE s.r.o., Plzeň 3, 301 00, Czechia|Fakultni nemocnice Kralovske Vinohrady, Praha, 100 00, Czechia|Diabetologická a endokrinologická ambulance Praha, Praha, 140 21, Czechia|Private Endocrnologist Dr Viitas, Pärnu, 80018, Estonia|East Tallinn Central Hospital, Tallinn, 10138, Estonia|Merelahe Family Doctors Centre, Tallinn, 10617, Estonia|Estonian Diabetes Centre, Tallinn, 13419, Estonia|Tartu University Hospital Internal Medicine Clinic, Tartu, 50406, Estonia|Institut für Klinische Forschung und Entwicklung, Berlin, 10437, Germany|Plassmann, Essen, 45359, Germany|Zentrum für klinische Forschung, Dr. med. Lüdemann, Falkensee, 14612, Germany|Diabetes Zentrum Wandsbek Berufsausuebungsgemeinschaft GbR, Hamburg, 22041, Germany|Wendisch/Dahl Hamburg, Hamburg, 22607, Germany|Institut für Diabetesforschung GmbH Münster - Dr. med. Rose, Münster, 48145, Germany|RED-Institut für medizinische Forschung und Fortbildung GmbH, Oldenburg in Holstein, 23758, Germany|Praxis Dr. med. Wenzl-Bauer, Rehlingen-Siersburg, 66780, Germany|PTE-AOK II. Belgyogyaszati Klinika es Nephrologiai Centrum, Pécs, Baranya Vármegye, 7623, Hungary|Selye János Kórház és Rendelőintézet, Komárom, Komárom-Esztergom, 2900, Hungary|Óbudai Egészségügyi Centrum, Budapest, 1036, Hungary|Szőcs Depot Egészségügyi Szolgáltató Kft., Budapest, 1042, Hungary|Bajcsy-Zsilinszky Kórház, Budapest, 1106, Hungary|Debreceni Egyetem Klinikai Központ Belgyógyászati Klinika D épület, Debrecen, 4043, Hungary|Debreceni Egyetem Klinikai Központ Belgyógyászati Klinika, Debrecen, H-4032, Hungary|Markusovszky Egyetemi Oktatókórház, Szombathely, 9700, Hungary|Fejér Megyei Szent György Oktatókórház, Székesfehérvár, 8000, Hungary|Endolife Specialty Hospitals, Guntur, Andhra Pradesh, 522001, India|Care Outpatient Centre, Hyderabad, Andhra Pradesh, 500034, India|Fortis Hospital, Shalimar Bagh, New Delhi, New Delhi, Delhi, 110088, India|Nirmal Hospital Pvt. Ltd., Surat, Gujarat, 395002, India|PGIMS Rohtak, Rohtak, Haryana, 124001, India|KLES & Prabhakar Kore Hospital and Research Centre, Belgaum, Karnatka, 590010, India|Amrita Institute Of Medical Sciences & Research Centre, Kochi, Kerala, 682041, India|Seth GS medical college and KEM Hospital, Mumbai, Maharashtra, 400012, India|Deenanath Mangeshkar Hospital & Research Centre, Pune, Maharashtra, 411004, India|Deenanath Mangeshkar Hospital and Research Centre, Pune, Maharashtra, 411004, India|Inamdar Multispeciality Hospital, Pune, Maharashtra, 411040, India|Apollo Hospital, Delhi, New Delhi, 110076, India|All India Institute of Medical Sciences, New Dehli, New Delhi, 110029, India|Dayanand Medical College & Hospital, Ludhiana, Punjab, 141001, India|Christian Medical College Hospital, Vellore, Vellore, Tamil Nadu, 632004, India|Osmania General Hospital, Hyderabad, Telangana, 500012, India|Gandhi Hospital & Medical college, Hyderabad, Telengana, 500003, India|Gleneagles Hospitals, Hyderabad, Telengana, 500004, India|MV Hospital and Research Centre, Lucknow, Uttar Pradesh, 226003, India|I.P.G.M.E & R Hospital, Kolkata, West Bengal, 700020, India|Apollo Multispeciality Hospital, Kolkata, Kolkata, West Bengal, 700054, India|NZOZ Przychodnia Specjalistyczna Medica, Lublin, Lubelski, 20-538, Poland|Specjalistyczny Gabinet Diabetologiczny Radoslaw Rumianowski, Gorzow Wielkopolski, Lubuskie, 66-400, Poland|Uniwersytecki Szpital Kliniczny w Bialymstoku, Bialystok, Podlaskie Voivodeship, 15-276, Poland|NZOZ Specjalistyczny Osrodek Internistyczno-Diabetologiczny Małgorzata Arciszewska, Bialystok, Podlaskie, 15-435, Poland|Kresmed Sp. z o. o., Bialystok, Podlaskie, 15-481, Poland|Centrum Zdrowia Metabolicznego, Poznan, Wielkopolskie Voivodeship, 60-589, Poland|Osteo Medic s.c. Artur Racewicz Jerzy Supronik, Bialystok, 15-351, Poland|SNZOZ Lege Artis, Bialystok, 15-404, Poland|Centrum Kliniczno Badawcze, Elblag, 82-300, Poland|Centrum Badan Klinicznych PI-House, Gdansk, 80-546, Poland|Samodzielny Publiczny Zaklad Opieki Zdrowotnej Uniwersytecki Szpital w Krakowie, Krakow, 30-688, Poland|Centrum Terapii Współczesnej J.M. Jasnorzewska S.K.A., Lodz, 90-338, Poland|Gaja Poradnie Lekarskie, Poznan, 61-251, Poland|Centrum Medyczne "Diabetika", Radom, 26-600, Poland|NBR Polska Tomasz Klodawski, Warszawa, 00-710, Poland|Panstwowy Instytut Medyczny Ministerstwa Spraw Wewnetrznych I Administracji, Warszawa, 02-507, Poland|Centrum Medyczne Oporow, Wroclaw, 52-416, Poland|Prywatny Gabinet Janusz Gumprecht, Zabrze, 41-800, Poland|Manati Ctr For Clin Research, Manati, 00674, Puerto Rico|DIADA, s.r.o., Bardejov, 08501, Slovakia|Diabetologicka ambulancia Diabetes care, s.r.o., Hnusta, 98101, Slovakia|Diabetologicka ambulancia DIAMO s.r.o., Kezmarok, 06001, Slovakia|MOMED, s.r.o, Kralovsky Chlmec, 077 01, Slovakia|IN-DIA s.r.o., Lucenec, 984 01, Slovakia|DIABETOL, s.r.o., Presov, 080 01, Slovakia|OLIVER - MED s.r.o., Rimavska Sobota, 979 01, Slovakia|MEDI-DIA s.r.o., Sabinov, 08301, Slovakia|Diabetologicka ambulancia MUDr. Gabriela Zimova, Spisska Nova Ves, 052 01, Slovakia|General Hospital Celje, Celje, SI-3000, Slovenia|Healthcare Centre Koper, Koper, SI-6000, Slovenia|UKC Ljubljana, Endocrinology and Diabetes, Ljubljana, SI-1000, Slovenia|UKC Maribor - diabetes, Maribor, SI-2000, Slovenia|Healtcare Centre Nova Gorica, Nova Gorica, SI-5000, Slovenia|Taichung Veterans General Hospital, Taichung City, 407, Taiwan|National Cheng Kung University Hospital, Tainan, 704, Taiwan
|
